Lihua Chen

Dr. Lihua Chen


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2021 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
QZQilin Zhang
Qilin Zhang
WWWenqi Wu
Wenqi Wu
YFYuxin Fan
Yuxin Fan
YLYang Li
Yang Li
JLJing Liu
Jing Liu
WLweifeng luo
weifeng luo
Objectives: Effective strategy for the treatment of depression is limited. This study was to evaluate the safety and efficacy of botulinum toxin A (BoNT/A) in the treatment of depression.Methods: Seventy‐six patients were assigned to the BoNT/A group (n = 52) and sertraline control group (n = 24). For the BoNT/A group, BoNT/A was injected into the frowning muscle, depressor muscle, occipital frontalis muscle, lateral canthus, and bilateral temporal region at 20 sites. Five units per site and a total of 100 units of BoNT/A were given. Patients in the sertraline control group were medicated with sertraline 50–200 mg (114.58 ± 52.08 mg) per day. Depression was assessed by the 17‐item Hamilton Depression Scale (HAMD‐17), 14‐item Hamilton Anxiety Scale (HAMA‐14), Self‐rating Depression Scale (SDS), and Self‐rating Anxiety Scale (SAS). All participants were followed up for 12 weeks.Results: Scores of HAMD, HAMA, SDS, and SAS decreased significantly in both BoNT/A and sertraline groups after treatment for 12 weeks. Overall, there were no differences in decreased magnitude between the two groups (p > .05). The HAMA, SDS, and SAS results showed that the onset time of BoNT/A was earlier than that of sertraline. Side effects rates were 15.38% for BoNT/A and 33.33% for sertraline.Conclusion: This study demonstrated significant antidepressant effects of BoNT/A. The efficacy of BoNT/A was comparable with established antidepressant sertraline. The onset time of BoNT/A was earlier than sertraline, and the proportion of side effects was less than sertraline. Therefore, BoNT/A could be a safe and effective option for the treatment of depression.

8 August 2022 in International Immunopharmacology
Verified
Journal Article
Open access
YGYuhang Gong
Yuhang Gong
JQJianxin Qiu
Jianxin Qiu
JYJiajing Ye
Jiajing Ye
TJTing Jiang
Ting Jiang
WZWeikang Zhang
Weikang Zhang
ZHZhenghua Hong
Zhenghua Hong
As a degenerative disease, the pathogenesis and treatment of osteoarthritis (OA) are still being studied. The prevailing view is that articular cartilage dysfunction plays an essential role in the development of osteoarthritis. Similarly, dynamic bone remodeling dramatically influences the development of osteoarthritis. The inflammatory response is caused by the overexpression of inflammatory factors, among which tumor necrosis factor-α is one of the main causes of OA, and its sources include the secretion of chondrocytes themselves and osteoclast secretion of subchondral bone. Moreover, TNF-α-induced activation of RIP1, RIP3, and MLKL has been shown to play an important role in cell necroptosis and inflammatory responses. In vitro, AZ-628 alleviates chondrocyte inflammation and necroptosis by inhibiting the NF-κB signaling pathway and RIP3 activation instead of RIP1 activation. AZ-628 also reduces osteoclast activity, proliferation and differentiation, and release of inflammatory substances by inhibiting autophagy, MAPK, and NF-κB pathways. Similarly, the in vivo study demonstrated that AZ-628 could inhibit chondrocyte breakdown and lower osteoclast formation and bone resorption, thereby slowing down subchondral bone changes induced by dynamic bone remodeling and reversing the progression of osteoarthritis in mice. The results of this study indicate that AZ-628 could be used to treat OA byinhibiting chondrocyte necroptosis and regulating osteoclast formation.

14 February 2024 in International Journal of Behavioral Nutrition and Physical Activity
Verified
Journal Article
Open access
PDF file
LCLihua Chen
Lihua Chen
SSShi-Yu Sun
Shi-Yu Sun
GLGuijie Li
Guijie Li
XGXIANG GAO
XIANG GAO
WLWeifeng Luo
Weifeng Luo
FLFurong Li
Furong Li
Background: How physical activity (PA) and different sleep traits and overall sleep pattern interact in the development of Parkinson’s disease (PD) remain unknown. Objective: To prospectively investigate the joint associations of PA and sleep pattern with risk of PD. Methods: Included were 339,666 PD-free participants from the UK Biobank. Baseline PA levels were grouped into low (< 600 MET-mins/week), medium (600 to < 3000 MET-mins/week) and high (≥ 3000 MET-mins/week) according to the instructions of the UK Biobank. Healthy sleep traits (chronotype, sleep duration, insomnia, snoring, and daytime sleepiness) were scored from 0 to 5 and were categorized into “ideal sleep pattern” (≥ 3 sleep scores) and “poor sleep pattern” (0–2 sleep scores). Hazard ratios (HRs) and 95% confidence intervals (CIs) of PD were estimated by Cox proportional hazards models. Results: During a median of 11.8 years of follow-up, 1,966 PD events were identified. The PD risk was lower in participants with high PA (HR = 0.73; 95% CI: 0.64, 0.84), compared to those with low PA; and participants with ideal sleep pattern also had a lower risk of PD (HR = 0.78; 95% CI: 0.69, 0.87), compared to those with poor sleep pattern. When jointly investigating the combined effect, participants with both high PA and ideal sleep pattern had the lowest risk of incident PD (HR = 0.55; 95% CI: 0.44, 0.69), compared to those with low PA and poor sleep pattern; notably, participants with high PA but poor sleep pattern also gained benefit on PD risk reduction (HR = 0.74; 95% CI: 0.55, 0.99). Conclusions: Both high PA and ideal sleep pattern were independently associated with lower risk of developing PD, and those with both high PA level and ideal sleep pattern had the lowest risk. Our results suggest that improving PA levels and sleep quality may be promising intervention targets for the prevention of PD.

3 November 2021 in Frontiers in Nutrition
Verified
Journal Article
Open access
LCLihua Chen
Lihua Chen
QHQingjing Hu
Qingjing Hu
GLGuijie Li
Guijie Li
LZLi Zhang
Li Zhang
LQLi-Qiang Qin
Li-Qiang Qin
GXGuangfei Xu
Guangfei Xu
Background: The association between α-linolenic acid (ALA) and mortality is inconsistent and has not been summarized systematically.Objective: The purpose was to conduct a meta-analysis that synthesized the results of prospective cohort studies to investigate associations between ALA intake and mortality.Methods: We conducted a comprehensive search on PubMed, Embase, and Web of Science databases on May 1, 2021, for relevant prospective cohort studies which reported associations of ALA (assessed by dietary surveys and/or ALA concentrations in body tissues) with mortality from all-cause, cardiovascular disease (CVD), and other diseases. Multivariable-adjusted relative risks (RRs) were pooled by a random or fixed-effects model.Results: A total of 34 prospective cohort studies, of which 17 reported dietary ALA intake, 14 for ALA biomarkers, and the remaining 3 reported both of intake and biomarkers. The studies included 6,58,634 participants, and deaths were classified into all-cause mortality (56,898), CVD mortality (19,123), and other diseases mortality (19,061). Pooled RRs of ALA intake were 0.93 (95% CI: 0.86, 1.01, I2 = 71.2%) for all-cause mortality, 0.90 (95% CI: 0.83, 0.98, I2 = 22.1%) for CVD mortality, and 0.94 (95% CI: 0.83, 1.06, I2 = 73.3%) for other diseases mortality. The two-stage random-effects dose-response analysis showed a linear relationship between dietary ALA intake and CVD-mortality and each 0.5% energy increment of ALA intake was associated with a 5% lower risk of CVD-mortality (RR: 0.95; 95% CI: 0.90, 1.00). Pooled RRs per SD increment of ALA biomarkers were 0.99 (95% CI: 0.96, 1.01, I2 = 27%) for all-cause mortality, 1.00 (95% CI: 0.98, 1.03, I2 = 0%) for CVD mortality and 0.98 (95% CI: 0.95, 1.01, I2 = 0%) for other diseases mortality.Conclusions: This meta-analysis summarizing the available prospective cohort studies indicated that ALA intake was associated with reduced risk of mortality, especially CVD mortality. Our findings suggest that ALA consumption may be beneficial for death prevention. Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO; identifier: CRD42021264532.

8 January 2025 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
DLDong Liu
Dong Liu
ZLZiwei Liu
Ziwei Liu
YWYue Wu
Yue Wu
YHYan Hong
Yan Hong
JFJinghao Fang
Jinghao Fang
LCLihua Chen
Lihua Chen
Background: Triglyceride glucose (TyG) index has been proposed as a credible and simple surrogate indicator for insulin resistance. The primary aim of this study was to novelly examine the associations between dietary patterns reflecting variations in circulating TyG index and the risk of type 2 diabetes mellitus (T2DM).Methods: This study included 120,988 participants from the UK Biobank, all of whom completed multiple 24-h dietary assessments. Dietary pattern scores were derived using reduced-rank regression (RRR) and Least Absolute Shrinkage and Selection Operator (LASSO) regression, based on the TyG index and approximately 80 food groups. The associations between the TyG index, related dietary pattern scores, and T2DM risk were evaluated using Cox regression models.Results: During a median follow-up period of 11.2 years, 3,585 participants developed T2DM. A higher TyG index was significantly associated with an increased risk of T2DM. The two dietary patterns derived from RRR and LASSO showed a strong correlation (ρ = 0.88, p < 0.001) and shared similar characteristics at higher scores, including greater intakes of margarine, meat, fruit juice, and potatoes, alongside lower intakes of green vegetables, oily fish, yogurt, nuts and seeds, and dried fruits. Corresponding blood profiles, including elevated levels of C-reactive protein and HbA1c, along with reduced levels of HDL-C and docosahexaenoic acid, substantiated the dietary pattern assessments. The adjusted hazard ratios (HRs) for T2DM risk were 1.52 (95% CI: 1.33–1.73, p trend <0.001) and 1.48 (95% CI: 1.30–1.69, p trend <0.001) for dietary patterns derived using RRR and LASSO, respectively, comparing the highest to the lowest quintiles.Conclusion: The findings suggest that a higher TyG index and specific dietary patterns, characterized by higher intakes of margarine, meat, fruit juice, and potatoes, and lower intakes of green vegetables, oily fish, yogurt, nuts and seeds, and dried fruits, are associated with an increased risk of developing T2DM. These results underscore the potential of dietary modifications targeting these patterns to mitigate T2DM risk.

13 December 2021 in International Urology and Nephrology
Verified
Journal Article
Open access
PDF file
XAXiaojie Ang
Xiaojie Ang
YJYufeng Jiang
Yufeng Jiang
ZCZongqiang Cai
Zongqiang Cai
QZQi Zhou
Qi Zhou
MLMiao Li
Miao Li
XZXi Zhang
Xi Zhang
Purpose: This study aimed to combine plasma netrin-1 and clinical parameters to construct a diagnostic model for bladder pain syndrome/interstitial cystitis (BPS/IC). Methods: We analyzed the independent diagnostic value of netrin-1 and the correlation with clinical symptom scores of BPS/IC. Clinical parameters were selected using LASSO regression, and a multivariate logistic regression model based on netrin-1 was established, and then a nomogram of BPS/IC prevalence was constructed. The nomogram was evaluated using calibration curves, the C-index, and decision curve analysis (DCA). Finally, the model was validated using an internal validation method. Results: The area under the curve for the ability of netrin-1 to independently predict BPS/IC diagnosis was 0.858 (p < 0.001), with a sensitivity of 85% and specificity of 82%. The predicted nomogram included three variables: age, CD3 + /CD4 + T lymphocyte ratio, and netrin-1. The C-index of this nomogram was 0.882, and the predicted values were highly consistent with the actual results in the calibration curve. In addition, the internally validated C-index of 0.870 confirms the high reliability of the model. DCA results show that the net patient benefit of the netrin-1 combined with other clinical parameters was higher than that of the single netrin-1 model. Conclusion: Netrin-1 can be used as a diagnostic marker for BPS/IC and is associated with pain. The nomogram constructed by combining netrin-1 and clinical parameters was able to predict BPS/IC with great accuracy. In addition, Netrin-1 may also serve as a novel therapeutic target for BPS/IC.